[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fawzW26fP8viEweE7YtPGuCG1EIbbwJj8jpvKfK-y_M4":8,"$fNc4Kj9gsxmjyhNdrdXT5B_XTyPnOPSg0nCu-OlxvajQ":55,"$fkKTThghKe8Si_wheSo5rS-JU3bV2ZS4H2Ci5NnzpcCk":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65708,867568,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//Qwz6GyCWTi4XHRajDQhvP0c86fSiOy65.png","李文旭","温州老年病医院","肿瘤科","主治医师",317,0,"胰腺恶性肿瘤放化疗用药安全指南（化疗药物为主）","","https://ystcdn.venuertc.com/venue/AI/3034f00e-cba3-43c7-b3cf-a0b87c8674a6.jpg","\u003Cdiv id=\"material_title\" class=\"custom-pancreatic-cancer-title\">\n  胰腺恶性肿瘤放化疗用药安全指南（化疗药物为主）\n\u003C/div>\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #e7f0fa 0%, #f2f6fc 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 化疗药品的种类与核心机制 💊\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      化疗在胰腺恶性肿瘤治疗方案中扮演重要角色，主要药品包括吉西他滨（Gemcitabine）、紫杉醇类（如白蛋白结合型紫杉醇 Nab-paclitaxel）、氟尿嘧啶类（如5-FU），还有一些联合用药方案。以下是主要药品的机制简析：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\u003Cstrong>吉西他滨：\u003C/strong>作为核苷类似物，阻断肿瘤细胞DNA合成，防止细胞分裂。\u003C/li>\n      \u003Cli>\u003Cstrong>白蛋白结合型紫杉醇：\u003C/strong>稳定细胞微管，使细胞无法完成分裂过程。\u003C/li>\n      \u003Cli>\u003Cstrong>5-氟尿嘧啶：\u003C/strong>通过影响核酸代谢，干扰细胞增殖。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      不同药品起效机制有别，但目标均是阻止肿瘤细胞增殖或加快其凋亡。\u003Cbr>\n      相关文献：Von Hoff, D. D., et al. (2013). \"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.\" \u003Cem>New England Journal of Medicine\u003C/em>, 369(18), 1691-1703.\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #fbfae7 0%, #fcfbe6 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 化疗用药时间与服用方法⏳\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      化疗药物大多通过静脉注射给药。具体方法如下：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        吉西他滨：通常作为静脉滴注，每周一次或每三周一个周期，具体方案因人而异。\n      \u003C/li>\n      \u003Cli>\n        白蛋白结合型紫杉醇：也是静脉注射，常与吉西他滨联用，按医嘱操作。\n      \u003C/li>\n      \u003Cli>\n        5-氟尿嘧啶：多为静脉持续输注或间断推注，有些方案需要多日连续。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：遵守医务人员制定的周期，不私自调整给药间隔或剂量。\n    \u003C/p>\n    \u003Cp>\n      用药前应确保饮食清淡，按医生指导补充足够水分，减少胃肠不适。\n    \u003C/p>\n    \u003Cp>\n      💡 \u003Cspan style=\"background:#f8ecd3; border-radius:4px; padding:2px 6px;\">案例分享：\u003C/span>有位48岁女性患者，在严格按周期接受吉西他滨和紫杉醇联合化疗期间，由于全程配合规范，治疗顺利进行，未出现严重不良反应。\u003Cbr>\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #e7faf1 0%, #ecfcf7 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 剂型特点与服用技巧\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      胰腺恶性肿瘤常用化疗药物均为注射剂。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>吉西他滨/紫杉醇：\u003C/strong>需由专业医护人员在医院或日间病房通过静脉泵慢慢推入，滴注过程应严密监测。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>5-氟尿嘧啶：\u003C/strong>有时采用持续静脉泵注，剂量和速度需精确把控。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：自行口服或注射化疗药品极为危险，一定在医疗机构内处理，不建议自行操作。\u003Cbr>\n      不同药品不可以混合使用于同一注射泵或静脉通道，避免药品间物理或化学反应导致药物效力变化。\n    \u003C/p>\n    \u003Cp>\n      🤔 服用期间如有注射部位不适，应立即告知护士处理。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #fbe7fa 0%, #fbf0fc 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用与联合用药注意🔗\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      胰腺恶性肿瘤化疗中，联合用药较为常见。以下是主要注意事项：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>吉西他滨 + 白蛋白紫杉醇：\u003C/strong>联合应用时要密切关注骨髓抑制，绝不自行添加其它药品。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>5-氟尿嘧啶：\u003C/strong>与某些抗病毒药或抗癫痫药并用时，需遵医嘱以防相互作用增强毒性。\n      \u003C/li>\n      \u003Cli>\n        所有化疗药与抗凝治疗、某些抗感染药之间可能增强出血风险。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：如正在服用其它药物，提前告知医生，避免隐瞒。不要自行服用逍遥散、感冒药等常规口服药，以免引发不良反应交叉。\n    \u003C/p>\n    \u003Cp>\n      数据显示，联合化疗时骨髓抑制发生率可达50%以上，需要定期监测血常规。（参考：Conroy, T., et al. \"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.\" \u003Cem>NEJM\u003C/em>, 2011, 364(19), 1817-1825）\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #e7f7fa 0%, #f2fcfc 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 特殊人群用药调整🧑‍⚕️\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      使用化疗药物时，特殊人群如老年人、肝肾功能减退者、孕妇哺乳期女性需格外谨慎。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>老年患者：\u003C/strong>多合并基础疾病，需比常规剂量适当减量，防止骨髓抑制、感染。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能异常：\u003C/strong>吉西他滨等排泄主要靠肾脏，功能异常时需下调剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇/哺乳期：\u003C/strong>所有主流化疗药品均禁止使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：完全遵医嘱，任何特殊生理状况下，须由医生做个体化调整，勿自行增减剂量。\n    \u003C/p>\n    \u003Cp>\n      🌟临床经验表明，合理调整剂量可显著减少严重不良事件的发生概率。（Ghadiany, M., et al., \"Chemotherapy regimens for pancreatic cancer: A literature review.\" \u003Cem>J Cancer Res Ther\u003C/em>, 2017, 13(2), 299-310）\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #f3fbf3 0%, #eafdea 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应及处理方法🔍\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      胰腺恶性肿瘤用化疗药物，最常见的副作用包括：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>恶心、呕吐：\u003C/strong>服化疗药期间多见，根据需要可加用止吐药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>骨髓抑制（白细胞、血小板减少）：\u003C/strong>定期监测血常规，数值异常需要暂停或调整剂量，配合升白药物或输血处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>脱发、皮疹：\u003C/strong>为暂时性改变，通常不需特殊处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>静脉炎：\u003C/strong>如注射部位疼痛、红肿需及时换针位并处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：服药期间出现上述副作用，及时就医，不要自行中断用药或添加药物。\u003Cbr>\n      说明书提示：吉西他滨严重不良反应发生率约3~5%，骨髓抑制最为突出。\n    \u003C/p>\n    \u003Cp>\n      🤒若高热、感染等症状，请第一时间通知医生，勿自行服用退烧或抗生素药品。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #faece7 0%, #fcf6f2 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存与有效期管理📦\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      化疗药物多为医院统一配发，未用完的药品应由医务人员妥善管理，不建议带回家自行保存。\u003Cbr>\n      但若需临时储存，需注意下列要求：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>注射剂：\u003C/strong>应存放在2~8℃冰箱内，避免高温、日晒。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>避免泄漏：\u003C/strong>瓶体、包装未密封勿打开，破损药品必须报医务人员处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期药品：\u003C/strong>不得使用，由专业人员回收销毁。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：化疗药物自行保存风险极大，尽量由医院按照规范储存。医院集中管理可最大程度保证药品安全有效。\n    \u003C/p>\n    \u003Cp>\n      参考说明书规定，吉西他滨注射液开封后需在24小时内用毕，逾期必须废弃。（参考：Gemcitabine Injection [Prescribing Information], Eli Lilly, 2022）\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #edf3fb 0%, #f8fafc 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服与过量处理🚨\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      胰腺恶性肿瘤化疗药品为特殊时期严控用药，漏服或过量情形均需医院处理。\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>漏服：\u003C/strong>请勿自行补用剩余药品，务必告知主管医生、护士，由专业人员评估后补充下一周期方案。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>过量服用：\u003C/strong>会引发严重骨髓抑制、器官损伤，务必即时送医抢救。切勿自行抢救或处理。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：遵循医院安排，不私自补服或增减剂量。有异常情况第一时间报告。\u003Cbr>\n      严重药品使用偏差的处理需依赖血常规及器官功能检测，不可在家处理。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #faf8ed 0%, #fbfbe7 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 放疗期间药物管理📅\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      胰腺恶性肿瘤放疗时辅助药物主要是改善放疗相关不适、不良反应。应用细节如下：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>放疗联合化疗：\u003C/strong>化疗药物时点与放疗周期严格一致，不能擅自更改次序。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>对症药物：\u003C/strong>如止吐药、止泻药、保护胃肠的药品，理应诸药不混用，严格按照医嘱。\u003C/li>\n      \u003Cli>\n        放疗期间补充维生素、矿物质或免疫增强剂需报备医生，勿盲目叠加使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      正确做法：所有辅助药物需明确用途，先征求医生意见后使用。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: linear-gradient(90deg, #eaf5fb 0%, #f6f9fd 100%);\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 用药规范与安全总结🎯\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cp>\n      胰腺恶性肿瘤放化疗药物使用涉及多重细节，规范操作是安全、有效治疗的核心。请始终牢记：\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>全部药品在医院或专业环境使用，不自行操作。\u003C/li>\n      \u003Cli>遵守医嘱，绝不自行调整药品用量。\u003C/li>\n      \u003Cli>所有不适及时报告，副作用需医院处置。\u003C/li>\n      \u003Cli>药物存放与处置全程由医生、护士管理。\u003C/li>\n      \u003Cli>联合用药及特殊人群操作流程严守规范。\u003C/li>\n      \u003Cli>不可混合药品，更不可私自增减药物种类。\u003C/li>\n      \u003Cli>漏服、过量、异常反应必须寻求医院支持。\u003C/li>\n    \u003C/ul>\n    \u003Cp>\n      规范用药可显著提高治疗效果、降低化疗风险。只要把握上述关键细节，大部分不良事件都可提前发现、防范、处理。\u003Cbr>\n      如有疑问，请及时与专业医药人员沟通，切勿自行决策。\n    \u003C/p>\n    \u003Cp>\n      \u003Cstrong>最重要的两点：\u003C/strong>放化疗用药只在医院完成，每步均需医务人员指导。遇到任何非预期情况，立即寻求专业帮助，绝不拖延。\n    \u003C/p>\n  \u003C/div>\n\u003C/div>\n\n\u003C!-- 文献引用部分 -->\n\u003Cdiv class=\"custom-pancreatic-cancer-section\" style=\"background: #f7fafc;\">\n  \u003Ch2 class=\"custom-pancreatic-cancer-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献 📚\u003C/h2>\n  \u003Cdiv class=\"custom-pancreatic-cancer-content\">\n    \u003Cul>\n      \u003Cli>\n        Von Hoff, D. D., et al. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. \u003Cem>New England Journal of Medicine\u003C/em>, 369(18), 1691-1703. \u003Cspan style=\"font-size:0.9em; color:#65788e;\">[APA]\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        Conroy, T., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 364(19), 1817-1825. \u003Cspan style=\"font-size:0.9em; color:#65788e;\">[APA]\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        Ghadiany, M., et al. (2017). Chemotherapy regimens for pancreatic cancer: A literature review. \u003Cem>J Cancer Res Ther\u003C/em>, 13(2), 299-310. \u003Cspan style=\"font-size:0.9em; color:#65788e;\">[APA]\u003C/span>\n      \u003C/li>\n      \u003Cli>\n        Gemcitabine Injection [Prescribing Information], Eli Lilly, 2022.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.custom-pancreatic-cancer-title {\n  font-size:32px;\n  font-weight:700;\n  color: #31609d;\n  padding:30px 0 10px 0;\n  text-align:center;\n  margin-bottom:24px;\n  letter-spacing:2px;\n}\n.custom-pancreatic-cancer-section {\n  border-radius:8px;\n  box-shadow:0 2px 8px rgba(70,129,188,.08);\n  margin-bottom:28px;\n  padding:24px 32px;\n  max-width:980px;\n  margin-left:auto;\n  margin-right:auto;\n}\n.custom-pancreatic-cancer-subtitle {\n  font-size:26px;\n  font-weight:600;\n  color: #1a4a73;\n  margin-bottom:14px;\n  text-align:left;\n  background:rgba(230,240,255,0.48);\n  border-radius:6px;\n  padding:10px 18px;\n  box-shadow:0 1px 3px rgba(70,129,188,0.05);\n  display: inline-block;\n}\n.custom-pancreatic-cancer-content {\n  font-size:18px;\n  color:#30495d;\n  line-height:1.88em;\n}\n.custom-pancreatic-cancer-content ul {\n  padding-left:28px;\n  margin:10px 0 16px 0;\n}\n.custom-pancreatic-cancer-content li {\n  margin-bottom:6px;\n  font-size:17px;\n  line-height:1.6em;\n}\n@media screen and (max-width:600px) {\n  .custom-pancreatic-cancer-section {\n    padding:14px 8px;\n  }\n  .custom-pancreatic-cancer-title {\n    font-size:22px;\n    padding:18px 0 6px 0;\n  }\n  .custom-pancreatic-cancer-subtitle {\n    font-size:18px;\n    padding:7px 12px;\n  }\n  .custom-pancreatic-cancer-content {\n    font-size:15px;\n  }\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"custom-pancreatic-cancer-title\">\n  胰腺恶性肿瘤放化疗用药安全指南（化疗药物为主）\n\u003C/div>\n\u003Cd",511,"2025-09-04 17:07:51","胰腺癌, 化疗药物, 吉西他滨, 白蛋白结合型紫杉醇, 5氟尿嘧啶, 不良反应, 药物相互作用, 用药管理","本指南详细解读胰腺恶性肿瘤化疗药物的种类、使用方法及注意事项，帮助患者安全有效地进行治疗，特别为特殊人群提供药物调整建议。","2025-09-08 11:31:19",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]